Legal Representation
Attorney
DANIEL HOPEN
USPTO Deadlines
Application History
38 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 12, 2024 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Aug 12, 2024 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Feb 14, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 13, 2024 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jan 9, 2024 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 29, 2024 | IROA | I | RESPONSE TO ITU OFFICE ACTION ENTERED | Loading... |
| Jan 29, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 11, 2024 | INCE | O | ITU OFFICE ACTION ISSUED FOR EXTENSION REQUEST | Loading... |
| Jan 9, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 19, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 18, 2023 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jul 11, 2023 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jul 18, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jul 11, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 12, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 10, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jan 10, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jan 10, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 1, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Aug 1, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Aug 1, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jul 12, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 27, 2022 | TMBN | T | TTAB RELEASE CASE TO TRADEMARKS | Loading... |
| May 27, 2022 | OP.T | T | OPPOSITION TERMINATED NO. 999999 | Loading... |
| May 27, 2022 | OP.D | T | OPPOSITION DISMISSED NO. 999999 | Loading... |
| May 19, 2021 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 | Loading... |
| Nov 25, 2020 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Nov 17, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 17, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 28, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 5, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 23, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Sep 23, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Sep 23, 2020 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Sep 23, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Sep 22, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 16, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 23, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Research in the field of pharmaceuticals for treatment of autoimmune diseases; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific study and research in the field(s) of medicine, namely, for the prevention and treatment of cancer, tumor, autoimmune diseases, diabetes, cardiovascular diseases, ophthalmic diseases, infectious diseases, and respiratory diseases
Classification
International Classes
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOPHARMA"